
Every LDL-lowering method lowers cardiac risk in proportion to the LDL reduction achieved
Louis shares a chart (originally from Dr. Daniel Chong) combining many trials of different LDL-lowering interventions. Risk reduction scales with the absolute LDL decrease regardless of mechanism: the two PCSK9 inhibitor trials lowered LDL ~1.9 mmol/L (76 mg/dL) with a more than 50% risk reduction versus placebo.








































